Company intelligence / Profile preview

POC Medical Systems

Livermore, California, United Statespocmedicalsystems.com ↗

Ownership: Private
Employees: ~11
Development stage: Preclinical

Overview

The company’s MammoAlert™ test provides rapid point-of-care breast cancer pre-screening results in about 30 minutes from a drop of blood using the Pandora CDx™ microfluidic platform. It aims to replace traditional ELISA-based lab tests with a portable, affordable solution suitable for both rural and urban settings. Clinical performance data such as sensitivity/specificity are not detailed in public sources.

Therapeutic areas: OncologyInfectious Diseases
Modalities: DeviceDiagnostic device
Industry: Protein Biomarker Diagnostics

Drug pipeline

2 assets

Pandora CDx

Pre-clinical

Indications: Cancer screening, Infectious disease screening

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on POC Medical Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on POC Medical Systems.

Explore the full profile